- PrSandoz® Hydrocortisone 2.5% is indicated for the treatment of corticosteroid-responsive dermatoses*.
- After the original pharmaceutical company withdrew it from the Canadian market, Sandoz is reintroducing hydrocortisone cream 2.5% to Canada.
- Sandoz Canada is currently the only manufacturer of hydrocortisone cream 2.5%
Boucherville, Quebec, June 7, 2019 - Sandoz Canada today announced the launch of PrSandoz® Hydrocortisone 2.5%, a cream indicated for the treatment of corticosteroid-responsive dermatoses for up to four weeks, in cases requiring a topical agent with anti-inflammatory and antipruritic properties.
PrSandoz® Hydrocortisone 2.5% differs from hydrocortisone 0.5% and 1.0% creams currently available over the counter in pharmacies by its higher hydrocortisone dosage. Sandoz® Hydrocortisone 2.5% is available in 225 g jars and 45 g tubes and is available by prescription from the physician.
The skin is the largest organ of the human body and plays several fundamental roles, including that of a protective barrier against external irritants. Skin diseases are varied and have different causes. They can be serious or benign, embarrassing or unsightly and even sometimes painful.
While the original pharmaceutical company withdrew it form the market 2017, Sandoz is reintroducing hydrocortisone cream 2.5% to the Canadian market and is the only manufacturer in Canada to date. Sandoz Canada offers an additional option for healthcare professionals to treat Canadian patients with inflammation or itching skin. Hydrocortisone cream 2.5% has a higher concentration than hydrocortisone 0.5% and 1.0% creams and allows healthcare professionals to have again multiple treatment choices.
Disclaimer
This press release contains forward-looking statements reagarding, amongst others, potential future revenues from the sale of Sandoz® Hydrocortisone 2.5%. You should not place undue reliance on these statements. These forward-looking statements reflect management's current beliefs and expectations regarding future events and involve known and unknown risks and significant uncertainties. Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results could differ materially from those set forth in the forward-looking statements. There can be no assurance that Sandoz® Hydrocortisone 2.5% will be submitted or approved for other additional indications or labelling in other markets, or at any particular time, nor can it be guaranteed that Sandoz® Hydrocortisone 2.5% will be approved by a regulatory body or will be commercially successful in the future. In particular, management's expectations regarding Sandoz® Hydrocortisone 2.5% could be affected by a number of factors, including: uncertainties inherent in research and development, including unexpected clinical study results and additional analysis of existing clinical data; unexpected regulatory actions, delays or government regulations in general; the company's ability to obtain or maintain intellectual property protection; general economic and industry conditions; the global trend towards streamlining healthcare costs, including constant pressure regarding pricing; unexpected manufacturing problems, and other risks and factors mentioned in form 20-F filed by Novartis AG with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of today and does not undertake any obligation to update any forward-looking statements described herein as a result of new information, future events or other circumstances.
About Sandoz
Sandoz International GmbH is a world leader in generics and biosimilars. As a division of the Novartis Group, our goal is to discover new ways to improve and extend people's lives. Through our innovative approaches to providing people around the world with access to high-quality medicines, we are helping society cope with growing healthcare needs. Our portfolio includes approximately 1,000 molecules and covers all major medical sectors. In 2017, we had sales of US$10.1 billion. Our products have treated more than 500 million patients and our goal is to treat one billion patients. Sandoz is headquartered in Holzkirchen, in the greater Munich area of Germany. For more information, visit www.sandoz.com.
Sandoz Canada is a division of Sandoz International GmbH, a world leader in generics and biosimilars and a subsidiary of the Swiss multinational Novartis AG. A true leader in its field, Sandoz Canada markets and distributes a wide range of generics, biosimilars and consumer or specialty
products. For more information, visit www.sandoz.ca.
®: PrSandoz® Hydrocortisone 2.5% is a registered trademark owned or used under licence by Sandoz Canada Inc.
References
* The product monograph available here:
//www.sandoz.ca/sites/www.sandoz.ca/files/11372-Sandoz%20Hydrocortisone%20Product%20Monograph.pdf
Information:
Isabelle Troïtzky
Sandoz Canada
Inc.
+1-450-641-4903, Ext. 2725
[email protected]